Difference between revisions of "Cytarabine (Ara-C)"
(delete regimens section) |
m |
||
| Line 1: | Line 1: | ||
| − | Also known as Ara-C. | + | Also known as Ara-C or cytosine arabinoside. |
==General information== | ==General information== | ||
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.hospira.com/_docs/Cytarabine%20483176-PROMOWEB.pdf Cytarabine (Cytosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabine.pdf Cytarabine (Cytosar) package insert (locally hosted backup)]</ref> | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.hospira.com/_docs/Cytarabine%20483176-PROMOWEB.pdf Cytarabine (Cytosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabine.pdf Cytarabine (Cytosar) package insert (locally hosted backup)]</ref> | ||
| Line 5: | Line 5: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 20:33, 8 March 2012
Also known as Ara-C or cytosine arabinoside.
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2]
Route: IV, IT, SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Cytarabine (Cytosar) patient drug information (Chemocare)[3]
- Cytarabine (Cytosar) patient drug information (UpToDate)[4]